Cygnus aims to begin clinicals with non-invasive OTC blood glucose monitor in mid-1996.
This article was originally published in The Tan Sheet
Executive Summary
CYGNUS THERAPEUTICS' NONINVASIVE BLOOD GLUCOSE MONITOR is expected to enter clinical trials by mid 1996, the company estimated. The wrist watch-type device, based on reverse iontophoresis technology, is still in preliminary stages of development and a clinical protocol for the study has not yet been designed. The study is expected to compare Cygnus' noninvasive device to a standard OTC blood glucose monitor that uses the finger-prick technique.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning